April 28, 2014 09:00 ET
- Highest full year revenue in Ceapro's history: Total sales increased by 26.3% or $1,359,000 over the year ended December 31, 2012- Income from operations before extraordinary items of $447,000 compared to a loss of $515,000 in 2012- Net Profit of $176,000 compared to a net loss of $538,000 in 2012
- Highest full year revenue in Ceapro's history: Total sales increased by 26.3% or $1,359,000 over the year ended December 31, 2012
- Income from operations before extraordinary items of $447,000 compared to a loss of $515,000 in 2012
- Net Profit of $176,000 compared to a net loss of $538,000 in 2012
EDMONTON, ALBERTA--(Marketwired - April 28, 2014) - Ceapro Inc. (TSX VENTURE:CZO) ("Ceapro" or the Company") today announced its financial results and operational highlights for the year ended December 31, 2013.
"Year 2013 will be remembered as the most solid year ever in the history of Ceapro. Not only did we achieve a net profit and the best sales results with a 26.3% increase over 2012, but we did it during a year of major investments for the acquisition of equipment and the construction of a new facility. Our dedicated employees deployed tremendous efforts to respond to the growing demand while working diligently to plan and implement our new state of the art bioprocessing facility" said Gilles Gagnon, President and CEO. "Also, this major achievement would have not been possible without the unconditional support and vote of confidence from our major long term partners, Symrise AG, Alberta Financial Services Corporation and AI Bio Solutions" he added.
FINANCIAL RESULTS FOR THE YEAR ENDED DECEMBER 31, 2013
2013 KEY OPERATIONAL HIGHLIGHTS
"2013 has been marked by significant strategic achievements as we continued to move our products through pipeline and materially strengthened our cash position. With these conditions combined with our current strong order book and upcoming strategic initiatives, we are well positioned to pursue our focused pipeline development strategy with dry formulations. This is an exciting time for all of us at Ceapro, as well as for our partners and shareholders " added Mr. Gagnon.
The complete financial statements are available for review on SEDAR at http://sedar.com/Ceapro and on the Company's website at www.ceapro.com.
About Ceapro Inc.
Ceapro Inc. is a Canadian growth-stage biotechnology company. Primary business activities relate to the development and commercialization of active ingredients for personal care and cosmetic industries using proprietary technology and natural, renewable resources. To learn more about Ceapro, visit www.ceapro.com.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Branko JankovicVice President and CFOCeapro Inc.T (Edmonton): 780.917.8376E: email@example.com
See all RSS Newsfeeds